keyword
MENU ▼
Read by QxMD icon Read
search

wearing off Parkinsonism

keyword
https://www.readbyqxmd.com/read/28919877/analysis-of-correlation-between-an-accelerometer-based-algorithm-for-detecting-parkinsonian-gait-and-updrs-subscales
#1
Alejandro Rodríguez-Molinero, Albert Samà, Carlos Pérez-López, Daniel Rodríguez-Martín, Sheila Alcaine, Berta Mestre, Paola Quispe, Benedetta Giuliani, Gabriel Vainstein, Patrick Browne, Dean Sweeney, J Manuel Moreno Arostegui, Àngels Bayes, Hadas Lewy, Alberto Costa, Roberta Annicchiarico, Timothy Counihan, Gearòid Ò Laighin, Joan Cabestany
BACKGROUND: Our group earlier developed a small monitoring device, which uses accelerometer measurements to accurately detect motor fluctuations in patients with Parkinson's (On and Off state) based on an algorithm that characterizes gait through the frequency content of strides. To further validate the algorithm, we studied the correlation of its outputs with the motor section of the Unified Parkinson's Disease Rating Scale part-III (UPDRS-III). METHOD: Seventy-five patients suffering from Parkinson's disease were asked to walk both in the Off and the On state while wearing the inertial sensor on the waist...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/28904447/levodopa-induced-dyskinesia-clinical-features-pathophysiology-and-medical-management
#2
Sanjay Pandey, Prachaya Srivanitchapoom
Levodopa-induced dyskinesia (LID) is commonly seen in Parkinson's disease patients treated with levodopa. This side effect is usually encountered after long duration of treatment, but occasionally, this may be seen even after few days or months of treatment. LID is broadly classified as peak-dose dyskinesia, wearing-off or off-period dyskinesia, and diphasic dyskinesia. Pathogenesis of LID is complex, and different neurotransmitters such as dopamine, glutamine, adenosine, and gamma-aminobutyric acid play important role altering the normal physiology of direct and indirect pathway of cortico-basal ganglia-thalamic loop responsible for fine motor control...
July 2017: Annals of Indian Academy of Neurology
https://www.readbyqxmd.com/read/28900068/-efficacy-of-topical-agents-for-symptomatic-treatment-of-rotigotine-patch-induced-skin-disorders
#3
Yuki Yasutaka, Shinsuke Fujioka, Hirotomo Shibaguchi, Fumiaki Kiyomi, Koyomi Hara, Kentaro Ogata, Yoshio Tsuboi, Hidetoshi Kamimura
Since the effect of a percutaneous absorption-type dopamine agonist (DA) preparation, rotigotine patch, stably persists by once-a-day application, this dosage form is appropriate for Parkinson's disease patients showing levodopa induced wearing off phenomenon. On the other hand, skin disorders, mainly application site reaction, are characteristic problems associated with use of the patch. In this study, to clarify the influence of a topical agent used to prevent or treat rotigotine patch-induced skin disorder on continuation of the patch application, patients who started rotigotine patch application at our hospital were retrospectively surveyed...
September 2017: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://www.readbyqxmd.com/read/28870576/istradefylline-improves-daytime-sleepiness-in-patients-with-parkinson-s-disease-an-open-label-3-month-study
#4
Keisuke Suzuki, Masayuki Miyamoto, Tomoyuki Miyamoto, Tomoyuki Uchiyama, Yuka Watanabe, Shiho Suzuki, Taro Kadowaki, Hiroaki Fujita, Takeo Matsubara, Hirotaka Sakuramoto, Koichi Hirata
BACKGROUND: Istradefylline, a selective adenosine A2A receptor antagonist, has been reported to improve daily "off time" and motor symptoms in patients with Parkinson's disease (PD). However, the effect of istradefylline on sleep problems has not been thoroughly investigated. METHODS: We evaluated the effect of istradefylline on daytime sleepiness, sleep disturbances, and motor symptoms in 22 PD patients who were affected by the wearing off phenomenon in an open-label, 3-month study...
September 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28781108/exenatide-once-weekly-versus-placebo-in-parkinson-s-disease-a-randomised-double-blind-placebo-controlled-trial
#5
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson, Yazhou Li, Iciar Aviles-Olmos, Thomas T Warner, Patricia Limousin, Andrew J Lees, Nigel H Greig, Susan Tebbs, Thomas Foltynie
BACKGROUND: Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of Parkinson's disease. We investigated whether these effects would be apparent in a clinical trial. METHODS: In this single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo once weekly for 48 weeks in addition to their regular medication, followed by a 12-week washout period...
August 3, 2017: Lancet
https://www.readbyqxmd.com/read/28777756/long-term-effects-of-safinamide-on-mood-fluctuations-in-parkinson-s-disease
#6
Carlo Cattaneo, Thomas Müller, Erminio Bonizzoni, Gabriele Lazzeri, Ioannis Kottakis, Charlotte Keywood
BACKGROUND: Mood disorders are very frequent in Parkinson's Disease (PD), and their effective treatment is still a major unresolved issue: growing evidence suggests that glutamatergic system dysfunction is directly involved. Safinamide is a drug with an innovative mechanism of action, dopaminergic and non-dopaminergic, that includes the reversible inhibition of the monoamine oxidase-B (MAO-B) enzyme and the modulation of excessive glutamate release through the use- and state-dependent blockade of the sodium channels...
August 4, 2017: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/28774283/effectiveness-of-spinal-cord-stimulation-for-painful-camptocormia-with-pisa-syndrome-in-parkinson-s-disease-a-case-report
#7
Hisanao Akiyama, Saki Nukui, Masashi Akamatu, Yasuhiro Hasegawa, Osamu Nishikido, Soichiro Inoue
BACKGROUND: Spinal cord stimulation (SCS) has recently been reported to be effective for truncal postural abnormalities such as camptocormia and Pisa syndrome in Parkinson's disease. In this case report, we describe a case of a woman with Parkinson's disease in whom SCS was effective for painful camptocormia with Pisa syndrome. CASE PRESENTATION: A 65-year-old woman was admitted to our hospital because of painful camptocormia. She had noticed resting tremor in the left upper limb and aprosody at 48 years of age...
August 3, 2017: BMC Neurology
https://www.readbyqxmd.com/read/28768964/the-risk-factors-for-the-wearing-off-phenomenon-in-parkinson-s-disease-in-japan-a-cross-sectional-multicenter-study
#8
Shinji Ouma, Jiro Fukae, Shinsuke Fujioka, Shosaburo Yamamoto, Taku Hatano, Asako Yoritaka, Yasuyuki Okuma, Ken-Ichi Kashihara, Nobutaka Hattori, Yoshio Tsuboi
Objective Parkinson's disease (PD) is a common, progressive, neurodegenerative disorder. With progression of PD, the wearing-off phenomenon occurs more frequently as a motor complication, decreasing the patient's quality of life. The aim of this study was to investigate the risk factors for the wearing-off phenomenon in Japanese PD patients. Methods All of the study participants were clinically diagnosed as having PD. Each patient was assessed for the wearing-off phenomenon based on the findings of clinical assessments and interviews that were conducted during a single visit...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28701947/protein-restricted-diets-for-ameliorating-motor-fluctuations-in-parkinson-s-disease
#9
REVIEW
Luxi Wang, Nian Xiong, Jinsha Huang, Shiyi Guo, Ling Liu, Chao Han, Guoxin Zhang, Haiyang Jiang, Kai Ma, Yun Xia, Xiaoyun Xu, Jie Li, Jing Y Liu, Tao Wang
Levodopa is considered to be the most effective symptomatic drug for Parkinson's disease (PD). As the disease progresses, however, the patients are likely to experience a reduced response to levodopa and develop motor fluctuations (i.e., end-of-dose wearing off and unpredictable "on-off"). Protein-rich diets and elevated plasma concentrations of large neutral amino acids have been proved to impair the therapeutic effect of levodopa by reducing its absorption and influx into the brain. On the other hand, the protein-restricted diets including low-protein diet (LPD), protein-redistribution diet (PRD) and PRD with use of low-protein products can all improve the efficacy of levodopa in patients with motor fluctuations...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/28681744/levodopa-dose-maintenance-or-reduction-in-patients-with-parkinson-s-disease-transitioning-to-levodopa-carbidopa-entacapone
#10
Jongkyu Park, Younsoo Kim, Jinyoung Youn, Phil H Lee, Young H Sohn, Seoung B Koh, Jee-Young Lee, Jong S Baik, Jin W Cho
BACKGROUND: Levodopa bioavailability is enhanced by adding entacapone. However, the optimal dose of levodopa while transitioning to levodopa/carbidopa/entacapone (LCE) in Parkinson's disease (PD) during the wearing-off period is unclear. AIMS: The relative therapeutic efficacy and safety of different doses of levodopa were assessed when transitioning to the LCE combination for optimizing combined levodopa therapy. MATERIALS AND METHODS: A randomized, multicenter, double-arm, open-label study was conducted in Korea...
July 2017: Neurology India
https://www.readbyqxmd.com/read/28671144/a-novel-p-glu298lys-mutation-in-the-acmsd-gene-in-sporadic-parkinson-s-disease
#11
Dolores Vilas, Rubén Fernández-Santiago, Elena Sanchez, Luis J Azcona, Meritxell Santos-Montes, Pilar Casquero, Lucía Argandoña, Eduardo Tolosa, Coro Paisán-Ruiz
BACKGROUND: Common genetic variability in the ACMSD gene has been associated with increased risk for Parkinson's disease (PD) but ACMSD mutations in clinical cases of PD have so far not been reported. OBJECTIVE: To describe a case of sporadic PD carrying a novel ACMSD mutation. METHODS: As part of a genetic study to identify potential pathogenic gene defects related to PD in the Mediterranean island Menorca, an initial group of 62 PD patients underwent mutational screening using a panel-based sequencing approach...
2017: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/28451382/roles-of-functional-catechol-o-methyltransferase-genotypes-in-chinese-patients-with-parkinson-s-disease
#12
Qin Xiao, Yiwei Qian, Jiujiang Liu, Shaoqing Xu, Xiaodong Yang
BACKGROUND: Recent studies have found that the functional catechol-O-methyltransferase (COMT) gene may be associated with the susceptibility to and pharmacotherapy of Parkinson's disease (PD). In this case-control study, we investigated the most common functional COMT gene haplotypes that had been shown to influence COMT enzymatic activity and the association of the single and combined COMT haplotypes with clinical symptoms and pharmacotherapy in Chinese patients with PD. METHODS: One hundred forty-three patients with idiopathic PD and 157 healthy individuals were enrolled in this study...
2017: Translational Neurodegeneration
https://www.readbyqxmd.com/read/28279596/clinical-manifestations-of-nonmotor-symptoms-in-1021-japanese-parkinson-s-disease-patients-from-35-medical-centers
#13
MULTICENTER STUDY
Tetsuya Maeda, Yasushi Shimo, Shih-Wei Chiu, Takuhiro Yamaguchi, Kenichi Kashihara, Yoshio Tsuboi, Masahiro Nomoto, Nobutaka Hattori, Hirohisa Watanabe, Hidemoto Saiki
INTRODUCTION: We aimed to investigate the prevalence and severity of nonmotor symptoms (NMSs) and to identify factors affecting NMSs and the health-related quality of life of Japanese patients with Parkinson's disease (PD). METHODS: A total of 1021 patients with PD who had one or more NMS and showed wearing-off under anti-parkinsonian treatment were enrolled from 35 medical centers in Japan for this observational study. The primary measurements were the Movement Disorder Society unified Parkinson's disease rating scale (MDS-UPDRS) part I and the Parkinson's Disease Questionnaire (PDQ-8)...
May 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28273839/parkinson-s-disease-from-pathogenesis-to-pharmacogenomics
#14
REVIEW
Ramón Cacabelos
Parkinson's disease (PD) is the second most important age-related neurodegenerative disorder in developed societies, after Alzheimer's disease, with a prevalence ranging from 41 per 100,000 in the fourth decade of life to over 1900 per 100,000 in people over 80 years of age. As a movement disorder, the PD phenotype is characterized by rigidity, resting tremor, and bradykinesia. Parkinson's disease -related neurodegeneration is likely to occur several decades before the onset of the motor symptoms. Potential risk factors include environmental toxins, drugs, pesticides, brain microtrauma, focal cerebrovascular damage, and genomic defects...
March 4, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28255499/lsvt-big-improves-updrs-iii-scores-at-4-weeks-in-parkinson-s-disease-patients-with-wearing-off-a-prospective-open-label-study
#15
Tatsuya Ueno, Megumi Sasaki, Haruo Nishijima, Yukihisa Funamizu, Tomoya Kon, Rie Haga, Akira Arai, Chieko Suzuki, Jin-Ichi Nunomura, Masayuki Baba, Masahiko Tomiyama
The efficacy of LSVT-BIG for advanced Parkinson's disease (PD) patients with wearing off remains to be determined. Therefore, we evaluated whether LSVT-BIG improves motor disability in eight PD patients with wearing off. Unified Parkinson's Disease Rating Scale (UPDRS) scores, daily off time, and mobility assessments were evaluated during the "on" time before and after the LSVT-BIG course. LSVT-BIG significantly improved UPDRS III scores at 4 weeks and UPDRS II scores in the "off" state at 12 weeks, with no changes in the other measures...
2017: Parkinson's Disease
https://www.readbyqxmd.com/read/28243505/optimizing-extended-release-carbidopa-levodopa-in-parkinson-disease-consensus-on-conversion-from-standard-therapy
#16
REVIEW
Alberto J Espay, Fernando L Pagan, Benjamin L Walter, John C Morgan, Lawrence W Elmer, Cheryl H Waters, Pinky Agarwal, Rohit Dhall, William G Ondo, Kevin J Klos, Dee E Silver
PURPOSE OF REVIEW: To help clinicians optimize the conversion of a patient's Parkinson disease pharmacotherapy from immediate-release carbidopa/levodopa (IR CD/LD) to an extended-release formulation (ER CD/LD). RECENT FINDINGS: Eleven movement disorders specialists achieved consensus positions on the modification of trial-based conversion guidelines to suit individual patients in clinical practice. SUMMARY: Because the pharmacokinetics of ER CD/LD differ from those of IR CD/LD, modification of dosage and dosing frequency are to be expected...
February 2017: Neurology. Clinical Practice
https://www.readbyqxmd.com/read/28157097/combination-therapy-with-zonisamide-and-antiparkinson-drugs-for-parkinson-s-disease-a-meta-analysis
#17
Shinji Matsunaga, Taro Kishi, Nakao Iwata
BACKGROUND: There is uncertainty about the efficacy and tolerability of zonisamide for Parkinson's disease (PD). OBJECTIVE: We performed a meta-analysis of zonisamide treatment in PD patients who received antiparkinson drugs such as levodopa. METHODS: The primary outcome measures were the Unified Parkinson's Disease Rating Scale (UPDRS) Part III scores, wearing-off time, and discontinuation rate due to all causes. Secondary outcome measures were UPDRS total and subscale scores; discontinuation rates due to adverse events, inefficacy, and death; and individual adverse events...
2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28123403/the-epigenome-as-a-therapeutic-target-for-parkinson-s-disease
#18
REVIEW
Shane V Hegarty, Aideen M Sullivan, Gerard W O'Keeffe
Parkinson's disease (PD) is a common, progressive neurodegenerative disease characterised by degeneration of nigrostriatal dopaminergic neurons, aggregation of α-synuclein and motor symptoms. Current dopamine-replacement strategies provide symptomatic relief, however their effectiveness wear off over time and their prolonged use leads to disabling side-effects in PD patients. There is therefore a critical need to develop new drugs and drug targets to protect dopaminergic neurons and their axons from degeneration in PD...
November 2016: Neural Regeneration Research
https://www.readbyqxmd.com/read/28091751/long-term-treatment-of-parkinson-s-disease-with-levodopa-and-other-adjunctive-drugs
#19
Yoshikuni Mizuno, Satoe Shimoda, Hideki Origasa
We report a long-term treatment of Parkinson's disease in out-patient clinics. The patients with Parkinson's disease were evaluated at the time of clinic visit from September 1st, 2015 to February 29th, 2016. Total number of the patients was 498. The age at the evaluation was 69.9 ± 9.3 years and the age of onset was 60.2 ± 11.3. Hoehn and Yahr severity was 3.28 ± 0.94 in patients who were from 16 to 20 years (n = 53) and 3.00 ± 0.86 in patients from 21 years or more (n = 38) from the onset of the disease to the evaluation...
January 16, 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/27942720/assessment-of-safety-and-efficacy-of-safinamide-as-a-levodopa-adjunct-in-patients-with-parkinson-disease-and-motor-fluctuations-a-randomized-clinical-trial
#20
RANDOMIZED CONTROLLED TRIAL
Anthony H V Schapira, Susan H Fox, Robert A Hauser, Joseph Jankovic, Wolfgang H Jost, Christopher Kenney, Jaime Kulisevsky, Rajesh Pahwa, Werner Poewe, Ravi Anand
Importance: Although levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its use is often limited by wearing off effect and dyskinesias. Management of such complications continues to be a significant challenge. Objective: To investigate the efficacy and safety of safinamide (an oral aminoamide derivative with dopaminergic and nondopaminergic actions) in levodopa-treated patients with motor fluctuations. Design, Setting, and Participants: From March 5, 2009, through February 23, 2012, patients from academic PD care centers were randomized (1:1 ratio) to receive double-blind adjunctive safinamide or placebo for 24 weeks...
February 1, 2017: JAMA Neurology
keyword
keyword
98420
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"